WO2003053439A1 - Utilisation de derives de benzofuroxan comme agents anti-plaquettes - Google Patents
Utilisation de derives de benzofuroxan comme agents anti-plaquettes Download PDFInfo
- Publication number
- WO2003053439A1 WO2003053439A1 PCT/IB2002/005353 IB0205353W WO03053439A1 WO 2003053439 A1 WO2003053439 A1 WO 2003053439A1 IB 0205353 W IB0205353 W IB 0205353W WO 03053439 A1 WO03053439 A1 WO 03053439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzofuroxan
- carbonyl
- lower alkyl
- hydrogen
- pharmaceutically acceptable
- Prior art date
Links
- OKEAMBAZBICIFP-UHFFFAOYSA-N 3-oxido-2,1,3-benzoxadiazol-3-ium Chemical class C1=CC=CC2=[N+]([O-])ON=C21 OKEAMBAZBICIFP-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 229940127218 antiplatelet drug Drugs 0.000 title claims abstract description 17
- 239000000106 platelet aggregation inhibitor Substances 0.000 title abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 150000004677 hydrates Chemical class 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 86
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- -1 benzofuroxan compound Chemical class 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 239000001301 oxygen Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229960002479 isosorbide Drugs 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 4
- 239000001913 cellulose Chemical class 0.000 claims 2
- 229920002678 cellulose Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical class OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000001506 calcium phosphate Chemical class 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical class [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 229910021485 fumed silica Inorganic materials 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000000702 anti-platelet effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000561 aggregant Substances 0.000 description 4
- 238000013176 antiplatelet therapy Methods 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JCSIZMVUEBODFZ-UHFFFAOYSA-N 4-amino-3-bromo-5-nitrobenzoic acid Chemical compound NC1=C(Br)C=C(C(O)=O)C=C1[N+]([O-])=O JCSIZMVUEBODFZ-UHFFFAOYSA-N 0.000 description 3
- XPTLKSOTZZAJEW-UHFFFAOYSA-N 4-azido-3-bromo-5-nitrobenzoic acid Chemical compound OC(=O)c1cc(Br)c(N=[N+]=[N-])c(c1)[N+]([O-])=O XPTLKSOTZZAJEW-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000003257 anti-anginal effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 3
- 229960002497 nicorandil Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZZNAYFWAXZJITH-UHFFFAOYSA-N 4-amino-3-nitrobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1[N+]([O-])=O ZZNAYFWAXZJITH-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- QKGBRANQIWBMED-UHFFFAOYSA-N COCCN(CCC1)C1=O Chemical compound COCCN(CCC1)C1=O QKGBRANQIWBMED-UHFFFAOYSA-N 0.000 description 1
- JAEQOSKUYPMJAT-UHFFFAOYSA-N COCCN1CCOCC1 Chemical compound COCCN1CCOCC1 JAEQOSKUYPMJAT-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- ZTCLCSCHTACERP-AWEZNQCLSA-N N-[(1S)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]ethyl]-2-(difluoromethoxy)acetamide Chemical compound C1=C(C=C(C(=C1Cl)COC1=CC=CC2=C(C=3N(N=CN=3)C)C=C(C)N=C12)[C@@H](NC(=O)COC(F)F)C)F ZTCLCSCHTACERP-AWEZNQCLSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SJZLOWYUGKIWAK-UHFFFAOYSA-N n-(2-hydroxyethyl)pyridine-3-carboxamide Chemical compound OCCNC(=O)C1=CC=CN=C1 SJZLOWYUGKIWAK-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Definitions
- the present invention relates to the use of benzofuroxan compounds of general formula (I) as defined herein, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, as antiplatelet agents.
- the compounds are found to be potent inhibitors of platelet aggregation in the treatment of cardiovascular diseases.
- Antiplatelet agents' are those compounds, which either prevent adhesion, activation or aggregation of platelets.
- Antiplatelet drug therapy can be used in treatment or prevention of myocardial infarction, unstable angina, venous thromboembolism, coronary artery bypass graft (CABG), percutaneous transluminal angioplasty (PTCA), cerebrovascular disease like stroke, atrial fibrillation, prosthetic heart valve, valvular heart disease, acute peripheral occlusive disease, primary and secondary prevention of arterial thromboembolism, clot prevention in extra corporeal devices as the aetiology in all the above disease state is platelet activation and subsequent thrombus formation.
- CABG coronary artery bypass graft
- PTCA percutaneous transluminal angioplasty
- cerebrovascular disease like stroke atrial fibrillation
- prosthetic heart valve valvular heart disease
- acute peripheral occlusive disease primary and secondary prevention of arterial thromboembolism
- Pharmacologic therapy with antiplatelet agents such as aspirin provide clinical benefit in acute ischemic syndromes.
- Prostaglandin Ei has been reported as a powerful endothelium derived inhibitor of platelet aggregation.
- PGEi Prostaglandin Ei
- PDE PGEi phosphodiesterase III inhibitors
- inotropic agents, amrinone and milrinone increase cAMP by inhibition of PDE III and inhibit platelet aggregation in vitro.
- the other anti-platelet aggregatory drug developed included cyclo-oxygenase and thromboxane synthase inhibitors, prostaglandin derivatives, thromboxane A 2 receptor antagonists, and GPIIb/IIIa antagonists, which apart from PDE inhibitors have been widely used in clinical situation (Schafer, 1996, Anti platelet therapy, Am. J. Med, 101, 199-209).
- the benzofuroxan compounds of the instant invention which can exhibit dual activity viz. antianginal as well as antiplatelet activity make them most suitable for cardiovascular applications. .
- the invention provides a group of benzofuroxan compounds, their derivatives, analogues, tautomers, stereoisomers, polymorphs, their pharmaceutically acceptable salts or solvates as antiplatelet agents.
- the invention also provides a method of treatment or prevention of disease conditions caused by formation of platelets in human and non-human mammals by administration of said benzofuroxan compounds, their derivatives, analogues, tautomers, stereoisomers, polymorphs, their pharmaceutically acceptable salts or solvates.
- the invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising the said benzofuroxan compounds, their derivatives, analogues, tautomers, stereoisomers, polymorphs, their pharmaceutically acceptable salts or solvates in admixture with a pharmaceutically acceptable diluent, carrier or excepient effective as an antiplatelet agent.
- the invention provides for use of said benzofuroxan compounds, their derivatives, analogues, tautomers, stereoisomers, polymorphs, their pharmaceutically acceptable salts or solvates in the manufacture of a medicament useful as an antiplatelet agent.
- the present invention relates to the new use of benzofuroxan compounds of formula (I),
- R is -C(O)-R ⁇ , halogen, acetoxy, -X-R 2 or -C(O) NR 3 R 4 , or C(O)Cl R ⁇ is -O- (CH 2 )
- n 1 to 6
- X is oxygen, sulfur, -C (O)-, or -C (O) O-
- R 2 is hydrogen, straight chain or branched lower alkyl (C ⁇ -C 8 ), aromatic, heteroaromatic, and substituted or unsubstituted saturated heterocyclic ring with one or two heteroatoms such as nitrogen or oxygen wherein substitution on nitrogen is with hydrogen or lower alkyl;
- R 3 and are independently hydrogen, straight chain or branched lower alkyl (Ci-
- R 3 and R 4 are linked together with or without a heteroatom selected from the group consisting of oxygen and nitrogen wherein substitution on nitrogen is with hydrogen or lower alkyl;
- Y is -NHC (O)- or oxygen
- R 5 is lower alkyl (C ⁇ -C 8 ), aromatic, heteroaromatic, and substituted or unsubstituted saturated heterocyclic ring with one or two heteroatoms such as nitrogen or oxygen wherein substitution on nitrogen is with hydrogen or lower alkyl;
- R 6 is hydrogen, nitro, lower alkyl or -C (O)-R ;
- R 7 is hydrogen, lower alkyl or aryl
- R 8 is hydrogen ; or "Ri" is selected from the group consisting of
- the substituent R 8 in the said compounds of formula is a halogen selected from the group F, CI, Br and I.
- the compounds of the present invention can be prepared according to the methods disclosed in US6,248,895 (Sankaranarayanan, 2001) and US 6,232,331 (Sankaranarayanan, 2001).
- PRP platelet rich plasma
- PPP platelet poor plasma
- PRP The anticoagulated blood sample was centrifuged at 250g for 10 minutes and the supernatant (PRP) removed carefully into a plastic tube, and retained at 18 - 26°C for the duration of the test.
- Preparation of PPP The sediment (cells) from the above contrifugation is again re-centrifuged at 1500g for 10 minutes and the supernatant (PPP) is collected and kept at 18 -26°C for the duration of the test.
- the compounds 31 and 10 were tested for their antiplatelet activity using E 840 aggregometer.
- the inhibition of platelet aggregation by the test compounds was studied according to the modified method of Nishikawa M, et al.1981 using three different platelet aggregation reagents viz. (a) Adenosine -5' - diphosphate (ADP) : 10 ⁇ M, (b) Collagen: 0.2 mg/ml and (c) Epinephrine: 10 ⁇ M. (All agonists are obtained from Sigma-Aldrich - 'platelet aggregation reagents'). Assay Procedure:
- test drug solution final cone, of 46 ⁇ M or 57 ⁇ M OR saline (for control) was added to the PRP cuvettes and incubated for 1 min. 5.
- the aggregant was brought to room temperature (18 - 26°C) and swirled to mix.
- the aggregation response was measured for 5 min or till the max response is reached. 8.
- the extent of aggregation was expressed by the maximum change of light transmission expressed as a percentage, taking the difference between light transmission for PRP and PPP as 100.
- test compound 31 showed good inhibitory activity of 92%, 88% and 84% respectively at concentration (46 ⁇ M) with the three aggregants ADP, epinephrine and collagen.
- the test compound 10 showed about 25% inhibition with epinephrine as aggregant, while at higher concentration it showed marked increase in inhibitory activity.
- Platelet aggregation induced by an aggregating agent has also measured using a whole blood aggregometer which monitors the change in the electrical-impedance. It is the first simple method by which aggregation of human platelets can be measured in their natural environment (Zwierzina and Kunz, 1985).
- the tests were performed using venous blood sample of normal healthy male volunteers, (non smokers, non alcoholics) who were not on any medication known to affect platelet aggregation for at least 2 weeks prior to the study.
- the anticoagulant used was 3.8% tri sodium citrate, in the ratio of 9:1.
- the samples were kept at room temperature until tested and the experiments were completed within 2-3 hrs of blood- collection (Zwierzina and Kunz, 1985; Mutsuhito kikura et al., 2000).
- the test compounds and the reference compound Nicorandil were tested for their antiplatelet activity using chronolog whole blood aggregometer.
- the inhibition of platelet aggregation by the test compounds was studied using the aggregate collagen (chrono-log corp, chrono-par 385 collagen reagent).
- benzofuroxan compounds useful for the invention may be prepared by the process as disclosed in US 6,248,895 and US 6,232,331.
- This compound can be prepared by the same method as described in Example 3 infra for Step 2 of Compound No. 37 using 5(6)-azidocarbonyl benzofuroxan (0.50 gm, 0.0024 mole) and N-(2-hydroxyethyl-2-pyrrolidinone)(0.32 gm, 0.0024 mole). Yield: 0.60 gm. m. p.. : 164-165°C
- Step 1 Preparation of 5(6)-azidocarbonyl benzofuroxan
- Step 2 Preparation of 5(6)- ⁇ 2-(3-pyridylcarbonylamino)-ethyl ⁇ oxy carbonyl amino benzofuroxan
- a solution of azido comp. (0.41 g, 0.002 mole, as prepared in step 1) in toluene (20 ml) was refluxed for 2 hrs.
- Added N-(2-hydroxyethyl)-nicotinamide (0.33 gm, 0.002 mole) to the above solution and refluxed for another 2 hr., cooled to the room temp, precipitated product filtered and dried.
- Step 2 Preparation of 4-azido-3-bromo-5-nitro benzoic acid.
- Step 4 Preparation of 5(6)-[4-bromo]-isopropyloxycarbonyl benzofijroxan
- Compound of Formula (I) is dissolved in propylene glycol and warmed to about 40 °C to obtain a clear solution.
- the volume of the above solution is made up with 0.9% sodium chloride solution.
- a tablet can be prepared with the compounds of the invention and following ingredients together in the proportions by weight specified below:
- Compound of Formula (I) is mixed with Starch and Microcrystalline Cellulose and granulated with Starch mucilage (prepared by gelatinizing starch in water). The wet mass is dried at 50°C and the dried granules are sized through ASTM #20 sieve. The sized granules are blended with Sodium Starch Glycolate and Magnesium Stearate and the blend was compressed into tablets using 7 mm punches to contain 25 mg of
- Compound of Formula (I) Other tablets may be compressed to contain 50, 75,100,
- the pharmaceutical composition can be in the range of 0.5 % to 90 % by weight of the total composition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002366756A AU2002366756A1 (en) | 2001-12-20 | 2002-12-13 | Use of benzofuroxan derivatives as antiplatelet agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34128301P | 2001-12-20 | 2001-12-20 | |
US60/341,283 | 2001-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003053439A1 true WO2003053439A1 (fr) | 2003-07-03 |
Family
ID=23336943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/005353 WO2003053439A1 (fr) | 2001-12-20 | 2002-12-13 | Utilisation de derives de benzofuroxan comme agents anti-plaquettes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002366756A1 (fr) |
WO (1) | WO2003053439A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2515413C2 (ru) * | 2012-07-05 | 2014-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Производные 1,2,5-оксадиазолов, обладающие анти-вич активностью, фармацевтическая композиция, способ ингибирования интегразы вич-1 |
CN114920722A (zh) * | 2021-06-02 | 2022-08-19 | 何黎琴 | 一种7-羟基-3-乙酰基香豆素肟类化合物、其制备方法及医药用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0431944A2 (fr) * | 1989-12-08 | 1991-06-12 | Merck & Co. Inc. | Dérivés de benzofurazane possédant des propriétés antiarythmiques |
EP0574726A1 (fr) * | 1992-06-10 | 1993-12-22 | Hoechst Aktiengesellschaft | Oxadiazole-1,2,5 oxydes-2 annelés et leur application comme agents pharmacologiques |
US5424326A (en) * | 1992-06-20 | 1995-06-13 | Cassella Aktiengesellschaft | Phenyl-1,2,5-oxadiazolecarboxamide-2-oxides, their preparation and their use |
WO1998035950A1 (fr) * | 1997-02-13 | 1998-08-20 | Cortex Pharmaceuticals, Inc. | Composes a base de benzofurazan renforçant l'activite du recepteur de l'ampa |
US6232331B1 (en) * | 1998-05-22 | 2001-05-15 | Torrent Pharmaceutical Ltd. | Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions |
-
2002
- 2002-12-13 WO PCT/IB2002/005353 patent/WO2003053439A1/fr not_active Application Discontinuation
- 2002-12-13 AU AU2002366756A patent/AU2002366756A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0431944A2 (fr) * | 1989-12-08 | 1991-06-12 | Merck & Co. Inc. | Dérivés de benzofurazane possédant des propriétés antiarythmiques |
EP0574726A1 (fr) * | 1992-06-10 | 1993-12-22 | Hoechst Aktiengesellschaft | Oxadiazole-1,2,5 oxydes-2 annelés et leur application comme agents pharmacologiques |
US5424326A (en) * | 1992-06-20 | 1995-06-13 | Cassella Aktiengesellschaft | Phenyl-1,2,5-oxadiazolecarboxamide-2-oxides, their preparation and their use |
WO1998035950A1 (fr) * | 1997-02-13 | 1998-08-20 | Cortex Pharmaceuticals, Inc. | Composes a base de benzofurazan renforçant l'activite du recepteur de l'ampa |
US6232331B1 (en) * | 1998-05-22 | 2001-05-15 | Torrent Pharmaceutical Ltd. | Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions |
Non-Patent Citations (3)
Title |
---|
GHOSH P B ET AL: "Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological activity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 11, no. 2, 1968, pages 305 - 11, XP002113125 * |
GHOSH, P. B. ET AL: "Potential antileukemic and immunosuppressive drugs. 3. Effects of homocyclic ring substitution on the in vitro drug activity of 4-nitrobenzo-2,1,3-oxadiazoles (4-nitrobenzofurazans) and their N-oxides (4-nitrobenzofuroxans)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 3, 1972, pages 255 - 260, XP002232282 * |
ZHANG W ET AL: "Synthesis and hypoxia-selective cytotoxicity of benzofuraxans and quinoline di-N-oxides", CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 1, no. 125, 1 July 1996 (1996-07-01), pages 1182, XP002113146, ISSN: 0009-2258 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2515413C2 (ru) * | 2012-07-05 | 2014-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Производные 1,2,5-оксадиазолов, обладающие анти-вич активностью, фармацевтическая композиция, способ ингибирования интегразы вич-1 |
CN114920722A (zh) * | 2021-06-02 | 2022-08-19 | 何黎琴 | 一种7-羟基-3-乙酰基香豆素肟类化合物、其制备方法及医药用途 |
CN114920722B (zh) * | 2021-06-02 | 2024-03-08 | 何黎琴 | 一种7-羟基-3-乙酰基香豆素肟类化合物、其制备方法及医药用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2002366756A1 (en) | 2003-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU208124B (en) | Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient | |
PL214701B1 (pl) | Pochodna piperydyny, kompozycja farmaceutyczna zawierajaca te pochodna oraz zastosowanie lecznicze tej pochodnej | |
EP0281459A1 (fr) | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant | |
WO1996014843A2 (fr) | Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases | |
JPH0641466B2 (ja) | ピラゾロトリアジン誘導体およびそれを含有するキサンチンオキシダーゼ阻害剤 | |
KR20130089264A (ko) | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 | |
UA46821C2 (uk) | Заміщені n-[(аміноімінометил або амінометил)феніл]пропіламіди, фармацевтична композиція, способи лікування та проміжні сполуки | |
EP0187977B1 (fr) | Dérivés de tétrahydroquinoline, leur procédé de préparation et compositions anti-ulcère gastrique les contenant | |
WO2014044113A1 (fr) | Dérivé de pyrazol[3,4-c] pyridine, son procédé de préparation et son utilisation comme médicament | |
KR0159517B1 (ko) | 헤테로 사이클릭 유도체, 그의 제조방법 및 치료용도 | |
HU198021B (en) | Process for producing new antiallergic and antitrombotic heterocyclic compounds and pharmaceutical compositions containing them | |
HU214627B (hu) | Eljárás 2,4- és 2,5-szubsztituált piridin-N-oxid-származékok, és hatóanyagként ezeket tartalmazó gyógyászati készítmények előállítására | |
PL140573B1 (en) | Method of obtaining new dihydropyridine derivatives | |
SK6012002A3 (en) | Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same | |
US4619938A (en) | Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors | |
EP1442026B1 (fr) | Derives de triazole utiles comme inhibiteurs de la cyclooxygenase (cox) | |
US9630915B2 (en) | Thromboxane receptor antagonists | |
NZ260505A (en) | Cyclic indole derivatives and medicaments thereof | |
JPS6157578A (ja) | 複素環式化合物 | |
HU209645B (en) | Process for producing heteroaryl-sulphonamido-carbazole derivatives | |
JPS61172861A (ja) | イソキノリントロンボキサンシンセターゼ阻害剤 | |
JP6695361B2 (ja) | 重水素化チエノピペリジン誘導体、調製方法、及びその使用 | |
JP2005527518A (ja) | 新規なカルコン(chalcone)誘導体とその使用 | |
EP0159652B1 (fr) | Dérivés de 4-phénylphtalazine, leur préparation et compositions pharmaceutiques les contenant | |
US5405848A (en) | Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 914/KOLNP/2004 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |